Hemisens Technologies

The submission references a legitimate early-stage company (Hemisens Technologies, ~$2.3M Seed funding) but is heavily penalized for critical inaccuracies and poor data quality. The project name 'StarClaw' appears unrelated to the company's actual cardiac imaging product ('Cardians'). Claims that the audience is 'everyone' and 'most people have used my product' are factually impossible for a specialized B2B medical device, suggesting either a test submission or significant user error. While the underlying technology (non-invasive cardiac imaging) has high potential utility, the submission fails to demonstrate it.